Pioneering a New Cancer Treatment Paradigm

Treatment resistance, cancer relapse and metastasis are often the unfortunate outcome for patients suffering from cancer. At HiberCell, we are navigating these under-explored regions of cancer biology through our differentiated pipeline of clinical-stage therapies. We believe that exploring pathways critical to adaptive stress and innate immunity is key to our vision of ‘imagining a world in which cancer doesn’t win’ and that our QuAD3 platform may be used to generate critical insights into these areas.

Pioneering a New Cancer Treatment Paradigm

Treatment resistance, cancer relapse and metastasis are often the unfortunate outcome for patients suffering from cancer. At HiberCell, we are navigating these under-explored regions of cancer biology through our differentiated pipeline of clinical-stage therapies. We believe that exploring pathways critical to adaptive stress and innate immunity is key to our vision of ‘imagining a world in which cancer doesn’t win’ and that our QuAD3 platform may be used to generate critical insights into these areas.

Overcoming Resistance by Targeting Adaptive Stress

We believe that adaptive stress is a critical tumor survival mechanism that may limit our ability to eliminate highly resistant cancer cells that can lead to disease progression and death. Despite the clinical improvements that have been made with the use of targeted therapies, cancer cells leverage adaptive stress pathways to adapt, survive, and become resistant to treatment.

We are leading the way in understanding how to target the adaptive stress response for cancer therapy. We believe blocking these key mechanisms that resistant cancer cells use to survive has the potential to provide efficacy and durability across the cancer landscape.

Our Approach to Novel Targeted and Immunological Therapies

HC-5404 & HC-7366

HC-5404 and HC-7366 are differentiated adaptive stress therapies designed to inhibit PERK and modulate GCN2, respectively — two kinases critical to the Unfolded Protein Response (UPR) and the Integrated Stress Response (ISR).

Modulating adaptive stress has the potential to target and directly eliminate treatment resistant cells and resolve the stress that limits an anti-cancer immune response.

Odetiglucan

Odetiglucan is a differentiated, systemically administered therapeutic candidate that modulates both the innate and adaptive immune system.

It binds to a unique combination of receptors on innate immune cells, reprogramming the tumor microenvironment to drive a strong anti-cancer immune response.

Visionaries in Oncology

Our team is led by bold thought leaders who believe that transformational discoveries are possible when you integrate and power rigorous, traditional drug discovery methods with computational excellence. We are always seeking like-minded innovators that think beyond the box to join our vision of ‘imagining a world in which cancer doesn’t win.’

Our QuAD³ Platform

Our proprietary QuAD³ (Quantum Artificial Intelligence Drug Discovery and Development) Platform leverages advanced quantum machine learning and artificial intelligence strategies to drive robust insights from analysis of high-dimensional,  genomic and multi-omic datasets. QuAD³ is designed to deconvolute the complexity of adaptive stress, which we believe will help us identify patients most likely to respond to our therapeutic candidates, while uncovering new actionable insights.

See our recent qML publication.